Assessing the prognosis of gastrointestinal stromal tumors: A growing role for molecular testing

American Journal of Clinical Pathology

Volumn 122, Issue 1, 2004, Pages 11-13

  Corless, Christopher L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CDKN2A GENE; CELL CYCLE; EDITORIAL; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GENE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; PDGFRA GENE; PRIORITY JOURNAL; PROGNOSIS;

EID: 3042722245     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/BUVLRQBVGU0N0L42     Document Type: Editorial

References (19)

1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
2. Verweij J, Van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target; results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer. 2003;39:2006-2011.
3. Rodriguez JA, Guarda LA, Rosai J. Mesenteric fibromatosis with involvement of the gastrointestinal tract: a GIST simulator: a study of 25 cases. Am J Clin Pathol. 2004;121:93-98.
4. Debiec-Rychter M, Wasag B, Stul M, et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol. 2004;202:430-438.
5. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-465.
6. Kindblom LG, Meis-Kindblom J, Bumming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): a population-based study of 600 cases [abstract]. Ann Oncol. 2003;13(suppl 5):157.
7. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
8. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
9. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer. 2002;38(suppl 5):S39-S51.
10. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689-695.
11. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342-4349.
12. Fletcher JA, Corless CL, Dimitrijevic S, et al, for the GIST Working Group. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST) [abstract]. Proc ASCO. 2003;22:815.
13. Debiec-Rychter M, Lasota J, Sarlomo-Rikala M, et al. Chromosomal aberrations in malignant gastrointestinal stromal tumors: correlation with c-KIT gene mutation. Cancer Genet Cytogenet. 2001;128:24-30.
14. Kim NG, Kim JJ, Ahn JY, et al. Putative chromosomal deletions on 9p, 9q and 22q occur preferentially in malignant gastrointestinal stromal tumors. Int J Cancer. 2000;85:633-638.
15. Schneider-Stock R, Boltze C, Lasota J, et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol. 2003;21:1688-1697.
16. Ricci R, Arena V, Castri F, et al. Role of p16/INK4a in gastrointestinal stromal tumor progression. Am J Clin Pathol. 2004;122:35-43.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. epub May 20, 2004.
18. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. epub April 29, 2004.
19. Levis M, Small D. Small molecule FLT3 tyrosine kinase inhibitors. Curr Pharm Des. 2004;10:1183-1193.